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Summary
Human monocyte-derived dendritic cells (DC) (MoDC) are utilized for
immunotherapy. However, in-vitro immunological effects are often not mir-
rored in vivo. We studied the tissue-homing potential of MoDC. Circulating
monocytes and DC expressed different tissue-homing markers and, during
in-vitro development of MoDC, homing marker expression was lost resulting
in a ‘homeless’ phenotype. Retinoic acid (RA) induced gut-homing markers
(b7 and CCR9) and a regulatory phenotype and function [decreased human
leucocyte antigen D-related (HLA-DR) and increased ILT3 and fluorescein
isothiocyanate (FITC-dextran uptake) in MoDC]. RA-MoDC were less
stimulatory and primed conditioned T cells with a gut-homing profile
(b7+CLA-). Unlike the normal intestinal microenvironment, that from
inflamed colon of ulcerative colitis (UC) patients did not induce regulatory
properties in MoDC. However, RA-MoDC maintained their regulatory gut-
specific properties even in the presence of UC microenvironment. Therefore,
MoDC may be ineffectual for immunotherapy because they lack tissue-
homing and tissue-imprinting specificity. However, MoDC rehabilitation
with gut-homing potential by RA could be useful in promoting immuno-
therapy in pathologies such as UC.
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Introduction
Dendritic cells (DC) are unique in their ability to generate
primary immune responses, determining both the nature
and type of immune responses [1,2]. Manipulation of DC
phenotype and function are promising strategies to
perform immunotherapy. However, due their low numbers
in human tissues, ‘naturally occurring’ human DC are not
the usual source of DC for human studies. Given their easy
accessibility and large numbers, monocyte-derived DC
(MoDC) generated from fresh circulating monocytes
during 5–7-day in-vitro culture are the standard human DC
model [3]. They may be reinjected in vivo to elicit their
function. This strategy has been proposed for individualized
immunotherapy in several pathologies [4–7]. Generation of
tolerogenic DC may help to restore homeostasis lost in the
gastrointestinal tract in patients with inflammatory bowel
disease (IBD) [7–10]. However, despite their in-vitro effi-
cacy, DC immunotherapy is far from ideal when translated
to the clinics. Factors affecting their success include prepa-
ration, source and dose of DC, route of administration,
antigen-pulsing strategy, maturation status and even the
selected antigen itself [5]. However, we consider that there is
an essential missing factor which may explain the lack of
efficacy in vivo: the compartmentalization of immune
responses through DC homing marker expression and
migration.
Immune responses are elicited in a tissue-/organ-specific
way. Immune compartmentalization is controlled by DC
which imprint tissue specific homing markers on stimu-
lated T cells, restricting their migration to target tissues
[11–14]. The requirement for tissue specificity for inducing
inflammation in the human gut has been demonstrated in
patients with Crohn’s disease where, despite systemic lym-
phocyte sensitization to antigens encountered through the
gut, inflammation was induced only by challenge with these
antigens in the gut, and not by skin challenge [15]. There-
fore, appropriate tissue specificity is likely to be required for
immunotherapy. However, information about the expres-
sion of homing markers on human DC themselves is scarce.
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We demonstrated recently that human peripheral circu-
lating DC display a multi-homing profile which may be
necessary for them to populate different tissues. However,
within skin and gut, DC express tissue-specific markers due
to the effect of the surrounding microenvironment [16].
Thus, multi-homing circulating human DC can acquire a
phenotype characteristic of gut tissue-specific DC when
cultured in the normal tissue microenvironment in vitro
[17–20]. Retinoic acid (RA), the active form of vitamin A,
mediates several tolerogenic properties of intestinal DC
[14,21–23], including the acquisition of gut-homing prop-
erties on human DC and their capacity to imprint gut-
homing properties on stimulated T cells [16]. However,
when human blood DC are cultured in vitro in the absence
of tissue factors and/or RA, DC lost expression of homing
markers [16].
We hypothesized that MoDC may also lose homing-
marker expression upon in-vitro culture during develop-
ment. Therefore, in this study we have (i) characterized the
homing profile of human circulating monocytes and subse-
quent MoDC in comparison with those of fresh blood DC;
and (ii) studied whether we could generate stable gut-
specific regulatory MoDC. Our findings revealed that
human MoDC displayed a homeless phenotype, but RA
rehabilitated them with a regulatory gut-homing profile
which was maintained even when exposed to an inflamed
microenvironment from ulcerative colitis (UC) patients.
Our findings may open new doors for performing targeted
tissue-specific immunotherapy.
Materials and methods
Blood samples and MoDC
Human peripheral blood was collected from healthy volun-
teers with no known autoimmune or inflammatory dis-
eases, allergies or malignancies, following informed
consent. Peripheral blood mononuclear cells (PBMC) were
obtained by centrifugation over Ficoll-Paque Plus (Amer-
sham Biosciences, Chalfont St Giles, UK). Monocytes were
obtained by positive selection of CD14+ cells from PBMC
[suspended in miniMACS buffer: phosphate-buffered
saline (PBS) containing 5% bovine serum albumin (BSA)
and 2 mM ethylenediamine tetraacetic acid (EDTA)] with
immunomagnetic beads (Miltenyi Biotech, Bisley, UK), fol-
lowing the manufacturer’s instructions. Human MoDC
were generated following 5-day culture (37°C, 5% CO2,
high humidity) of monocytes (0·5 million/ml/well) in
24-well microtitre plates (Becton Dickinson, Oxford, UK)
in complete medium [Dutch modified RPMI-1640 (Sigma-
Aldrich, Dorset, UK) containing 100 u/ml penicillin/
streptomycin, 2 mM L-glutamine and 10% fetal calf serum
(FCS) (TCS Cellworks, Buckingham, UK)] supplemented
with interleukin (IL)-4 (50 U/ml; Promega, Southampton,
UK) and granulocyte–macrophage colony-stimulating
factor (GM-CSF) (0·1 mg/ml; Promega) for 5 days. On day
5, MoDC were pooled, washed and cultured for 24 h
(0·5 million/ml) in complete medium in the presence of
different doses (10-6 M, 10-7 M, 10-8 M) of all-trans-retinoic
acid (RA) (Sigma-Aldrich), lipopolysaccharide (LPS)
(0·1 mg/ml; Sigma-Aldrich) or preconditioned with 10-6 M
RA for 2 h before being cultured subsequently for 22 h with
LPS after gentle RA-washing.
Colonic samples and UC biopsy conditioning
Colonic biopsies from inflamed areas of three UC patients
were collected in ice-chilled complete medium and cultured
within 1 h in complete medium in 24-well culture dishes
(one biopsy/well/ml) for 24 h, as explained previously [16].
Complete medium (1 ml) was added to empty wells and
incubated for use as a basal condition. Media were centri-
fuged and either medium-only or cell-free UC colonic
biopsy supernatants (UC-SN) were used to condition
MoDC for 24 h. All experiments used freshly obtained cul-
tured supernatants or medium. MoDC were also pulsed
(t = 2 h) with and without RA (10-6 M) and washed twice
before being conditioned.
Antibody labelling
Monoclonal antibodies with the following specificities, con-
jugations and clones were used: b7 [either phycoerythin
(PE) or PE-cyanin 5 (Cy5)] (FIB504), CCR5-fluorescein
isothiocyanate (FITC) (2D7/CCR5), CD3-PE-Cy5
(UCHT1), cutaneous lymphocyte-associated antigen (CLA)
(either FITC or biotin) (HECA-452), human leucocyte
antigen D-related (HLA-DR) (either FITC or PE-Cy5 (G46-
6), interferon (IFN)-g-allophycocyanin (APC) (XMG1·2)
and streptavidin-APC were purchased from BD Biosciences
(Oxford, UK); CCR4-APC (205410), CCR7-PE (150503),
CCR8-APC (191704), CCR9-PE (112509), CCR10-APC
(314315) and immunoglobulin-like transcript (ILT)-3 (PE)
(293623) were purchased from R&D Systems (Abingdon,
UK); CD14 (PE-Cy5) (TÜK4) and IL-10-PE (JES3-9D7)
were purchased from AbD Serotec (Oxford, UK). Appropri-
ate isotype-matched control antibodies were purchased
from the same manufacturers. Cells were labelled in PBS
containing 1 mM EDTA and 0·02% sodium azide [fluores-
cence activated cell sorter (FACS) buffer]. Labelling was
performed on ice and in the dark for 20 min. Cells were
washed twice in FACS buffer, fixed with 1% paraformalde-
hyde in 0·85% saline and stored at 4°C prior to acquisition
on the flow cytometer (within 48 h). For intracellular stain-
ing, cells were fixed with Leucoperm A following surface
staining, and permeabilized with Leucoperm B before
adding antibodies for intracellular labelling. After incuba-
tion cells were washed in FACS buffer, fixed and acquired
on the flow cytometer.
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Phagocytic activity of DC
Phagocytic activity of MoDC was determined by uptake of
FITC-dextran (molecular weight 40 kDa) (Sigma-Aldrich),
following the manufacturer’s instructions. Briefly, after con-
ditioning of MoDC with different doses of RA, MoDC were
incubated with 1 mg/ml of FITC-dextran for 2 h either
at 37°C or on ice (internal control), and then washed
twice in PBS. Flow cytometry acquisition was performed
subsequently.
Flow cytometry and data analysis
Data were acquired on a FACSCalibur cytometer (BD Bio-
sciences) and analysed using WinList version 5·0 software
(Verity, ME, USA). The proportion of cells positive for a
given marker was determined by reference to staining with
an isotype-matched control antibody. For single-parameter
analysis, WinList was used to subtract the normal cumula-
tive histogram for isotype control staining from a similar
histogram of staining with the test antibody using the
superenhanced Dmax (SED) normalized subtraction [24] to
obtain the percentage of positive cells for a given marker
and the intensity ratio (IR) of the staining of cells identified
as positive by the subtraction compared with that of the
isotype.
Proliferation assays
T cells (>95% pure) were obtained from freshly isolated
PBMC after depletion of CD14-, CD19- and HLA-DR-
positive cells with immunomagnetic beads (Miltenyi
Biotech, Bisley, UK). Alternatively, T cells were also depleted
for b7 expression using b7 APC-labelled antibody (BD Bio-
sciences) and anti-APC microbeads (Miltenyi Biotech)
(>95% CD3+b7-). In all cases, T cells were labelled with 5,6-
carboxyfluorescein diacetate succinimidyl ester (CFSE)
(Invitrogen Ltd, Paisley, UK), following the manufacturer’s
instructions. CFSE-labelled T cells (400 000) were incu-
bated for 5 days in round-bottomed 96-well microtitre
plates (Becton Dickinson) with different concentrations of
allogeneic MoDC (0, 1, 2 or 3% of T cells). Cells were har-
vested on day 5, and the proportion and phenotype of
stimulated T cells (CFSElow) were quantified by flow cytom-
etry within total CD3+ cells in the lymphocyte gate.
Statistical analyses
One- or two-way paired analysis of variance (anova) cor-
rected for multiple comparisons, or paired t-test, were
applied as stated in the figure legends. The level of signifi-
cance was fixed at P < 0·05.
Results
CCR9 and CCR7 were the predominant homing
markers on circulating monocytes
Human circulating monocytes were identified as CD14+
cells by flow cytometry (Fig. 1a). Homing-marker expres-
sion was determined by subtraction of isotype control
staining from the corresponding test staining (Fig. 1b) to
avoid any subjectivity in interpretation of the total percent-
age of cells which were positive for a given marker. No
gender differences in any of the assayed homing markers
(12 females and eight males) were detected (data not
shown).
Human circulating DC displayed a multi-homing profile
characterized mainly by co-expression of gut-homing b7
integrin and skin-homing CLA molecule, as described pre-
viously [16]. Conversely, gut- and lymph node-homing
markers [chemokine receptors (CCR)9 and CCR7, respec-
tively] were the predominant homing markers expressed by
circulating monocytes from healthy controls (Fig. 1c).
CCR5 (involved in migration to sites of inflammation) and
skin-homing molecule CLA were also expressed on some
circulating monocytes. CCR10 (associated with migration
to skin and mucosal sites), b7 integrin (gut-homing), CCR4
and CCR8 (both skin-homing) were virtually absent on cir-
culating monocytes (Fig. 1c).
Monocytes lost homing marker expression upon
differentiation into MoDC
Human monocytes were cultured for 5 days in a classic
in-vitro culture in the presence of IL-4 and GM-CSF to gen-
erate MoDC as assessed by up-regulated HLA-DR and loss
of expression of the monocyte marker CD14 with time
(Fig. 2). During in-vitro differentiation, monocytes lost
expression of all assayed homing markers, leaving day 5
MoDC with a ‘homeless’ profile (Fig. 2).
RA induced an immature, gut-homing phenotype
on MoDC
We next studied whether RA could induce a gut-homing
profile on MoDC. None of the assayed RA concentrations
had any effect on cell survival, as determined by total cell
numbers (data not shown).
When cultured with different doses of RA, MoDC
acquired expression of both b7 and CCR9 gut-homing
markers in a dose-dependent manner (Fig. 3a). We also
assessed the maturation status of RA-conditioned cells.
Because all MoDC expressed HLA-DR and the inhibitory
receptor ILT3 (data not shown), these markers were studied
by IR compared to the isotype control. Expression of both
markers increased in a dose-dependent fashion following
RA treatment (Fig. 3b), while RA also increased the phago-
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cytic capacity of MoDC, a characteristic of immature DC
for sampling antigen (Fig. 3b).
RA-conditioned MoDC had decreased T cell
stimulatory capacity and primed T cells with a
gut-homing profile
The stimulatory capacity of MoDC for allogeneic CFSE-
labelled T cells and the homing profile of stimulated T cells
were also studied. Consistent with the induced immature
phenotype (Fig. 3b), RA decreased the stimulatory capacity
of MoDC in a dose-dependent manner (Fig. 4a). We also
studied the homing-imprinting property of MoDC on
stimulated T cells (CFSElow). MoDC-stimulated T cells
(CFSElow) expressed CLA only, b7 only or were double-
positive or double-negative for both homing markers.
However, RA-conditioned MoDC, which had acquired a
gut-homing phenotype (Fig. 3a), also induced a gut-
homing phenotype on stimulated T cells via decreased
expression of CLA, rendering most of the stimulated T cells
potentially gut-homing with a b7+CLA- phenotype
(Fig. 4b). T cells stimulated by RA-conditioned MoDC were
mainly b7+CLA-, so we also studied the intensity of b7
expression via IR, proving that b7 expression was also
increased upon stimulation with RA-treated MoDC
(Fig. 4c).
RA-MoDC maintain their decreased stimulatory and
b7 T cell imprinting capacity in the presence of LPS
We next studied if the decreased stimulatory capacity of
RA-MoDC (Fig. 4a) was maintained in the presence of a
proinflammatory stimulus such as LPS. Also, as b7 was
expressed on both resting T cells and most dividing T cells
(irrespective of MoDC conditioning), we determined
whether b7 expression was imprinted by MoDC or due to
the selective survival of b7+ T cells.
b7- T cells were enriched from total PBMC (Fig. 5a) and
stimulated with MoDC that had been conditioned previ-
ously for 24 h with/without RA. Monocyte-derived DC had
also been conditioned with LPS (0·1mg/ml) for 24 h with/
without previous pulsing with 10-6 M RA for 2 h. Pretreat-
ment of MoDC with RA abrogated the increased
stimulatory capacity induced by LPS (Fig. 5b). RA-
conditioned DC also abrogated CLA expression on b7- T
cells and induced b7 expression, even following MoDC
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LPS conditioning after RA treatment (Fig. 5c,d). Thus, RA
specifically confers the ability of DC to prime gut-homing
T cells.
RA-MoDC maintained their gut-homing, immature
phenotype in the presence of colonic biopsy
supernatants from UC patients
The ability of RA to induce gut-homing and gut-
imprinting properties on MoDC may enable their use in
immunotherapy strategies to treat inflammatory patholo-
gies of the gastrointestinal tract, such as UC. However, DC
phenotype and function can be altered by the tissue micro-
environment [25]. Thus, although RA-MoDC maintained
their regulatory capacity even in the presence of LPS
(Fig. 5b), once DC enter the inflamed mucosal sites in vivo
they could potentially acquire proinflammatory properties
and even contribute to the ongoing inflammation [26,27].
Supporting this effect of the inflamed microenvironment
on DC, when human blood-enriched DC are exposed
colonic microenvironments from healthy controls [16] or
non-inflamed areas from UC patients [28] they acquire an
immature phenotype. However, when conditioned with
inflamed areas from UC patients, these properties are not
acquired. In this case, DC do not decrease their stimulatory
capacity and, furthermore, DC acquire an increased capac-
ity to prime responding T cells with a skin-homing profile
[28].
To address the effect of the UC microenvironment on
MoDC, cells – previously pulsed with and without 10-6 M
of RA – were conditioned with supernatants from colonic
biopsies of UC patients (inflamed areas; UC-SN). Similar to
blood-enriched DC [28], MoDC conditioned with UC-SN
did not differ in their stimulatory capacity from basal
MoDC (Fig. 6a). However, when MoDC had been pulsed
previously with 10-6 M RA, their stimulatory capacity
remained decreased compared with both basal (P < 0·05 at
3%) and no-RA supplemented with UC-SN MoDC
(P < 0·05 at 2% and P < 0·01 at 3% (Fig. 6a). RA-treated
MoDC retained their capacity to induce a gut-homing
profile on conditioned T cells following UC-SN condition-
ing with virtually none of the stimulated T cells expressing
CLA, unlike those MoDC conditioned with UC-SN without
previous RA pulsing (Fig. 6b,c).
Finally, we studied the cytokine profile of stimulated T
cells. Pulsing MoDC with RA prior to UC-SN conditioning
enabled MoDC to stimulate T cells with no proinflamma-
tory cytokine profile; the T cells had reduced IFN-g produc-
tion and increased IL-10 production compared with T cells
stimulated by MoDC conditioned with UC-SN only
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Fig. 5. Retinoic acid (RA) conditioned
dendritic cells (DC) maintain their decreased
stimulatory and gut-homing imprinting
capacity on b7- T cells in the presence of
lipopolysaccharide (LPS). (a) b7-negative T cells
were enriched from total peripheral blood
mononuclear cells (PBMC), as confirmed when
compared with the isotypes. (b) b7-negative T
cells were used to assess the stimulatory
capacity and (c) homing imprinting capacity of
DC conditioned previously with RA (24 h,
10-6 M), LPS (24 h, 0·1 mg/ml), RA (2 h, 10-6 M)
and subsequent LPS (22 h 0·1 mg/ml) or in
complete medium (basal). b7 and cutaneous
lymphocyte-associated antigen (CLA)
expression were determined on stimulated
[5,6-carboxyfluorescein diacetate succinimidyl
ester (CFSE)low] T cells. (d) One-way
repeated-measures analysis of variance (anova)
corrected for multiple comparisons was applied
on pooled data from three independent
experiments. P-value below 0·05 was considered
statistically significant; *P < 0·05; **P < 0·01.
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(Fig. 6d,e). Therefore, RA-conditioned MoDC exposed to
an inflamed microenvironment showed no evidence of
reversion towards a proinflammatory phenotype.
Discussion
Human circulating DC display a multi-homing b7+CLA+
profile [16] which was not shared by monocytes where
CCR9 and CCR7 were the main homing markers. The dif-
ferences between homing properties of DC and monocytes
may be determinants of their different tissue distributions.
Monocytes differentiated in vitro in the presence of IL-4
and GM-CSF lost expression of their homing markers and
failed to express those found on normal circulating DC,
rendering MoDC with a homeless phenotype. The complete
loss of homing markers studied in MoDC contrasts with the
multi-homing potential of circulating DC [16]. The home-
less phenotype of MoDC is likely to indicate incapacity to
home appropriately to skin or mucosal surfaces by these
in-vitro-generated DC. MoDC also failed to induce any
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tissue-specific homing profile of stimulated T cells as
opposed to tissue-resident DC [16]. This blanket loss in
homing potential may limit the in-vivo usefulness of these
cells for immunotherapy.
Human circulating monocytes and DC have different
immunological properties but also different homing marker
expression. Although both populations have ‘mixed’ or
multi-homing profiles, the homing markers that they
express are different. Circulating DC are mainly b7+CLA+
[16] (gut- and skin-homing). In contrast, both homing
markers are hardly expressed by circulating monocytes,
which are mainly CCR7+CCR9+ (lymph node- and small
bowel-homing markers) (Fig. 1). These differences might
account for different tissue distributions in vivo. During
in-vitro culture, in the absence of external factors mono-
cytes lose their homing marker expression (Fig. 2), render-
ing MoDC with a homeless phenotype different from that
of circulating DC. We cannot exclude expression of other
homing markers by MoDC. However, it is significant that all
studied homing markers were lost in time following in-vitro
differentiation to MoDC and that similar loss of homing
markers has been described in cultured blood DC [16].
Therefore, the loss of homing markers following in-vitro
culture in the absence of tissue and/or homing-inducing
factors may be a general mechanism in antigen-presenting
cells. Utilizing DC as therapeutic agents is effective in
autoimmune and inflammatory diseases, and DC are now
even being used to enhance survival rates of solid organ
transplants [5,7]. Practical issues of the small numbers of
DC obtainable from tissues predicate the use of MoDC for
immunotherapy in humans. However, we demonstrate here
that, unlike human blood and/or tissue DC, MoDC are
devoid of homing marker expression. Thus, when reinjected
in vivo into patients the lack of homing marker expression
may abrogate their trafficking into effector sites, providing
an explanation for the limited success of DC immuno-
therapy strategies in vivo [3].
DC control the migration of antigen-specific T cells to
target tissues by imprinting their own homing markers on T
cells that they stimulate [16], so antigen-specific T cells are
directed back to the target tissue where the antigen had
been sampled. The last aim of immunotherapy approaches
utilizing MoDC is to trigger T cell specific responses. Sub-
cutaneous immunization is the most clinically relevant
administration route. However, MoDC must enter lymph
nodes and present antigen, so MoDC used in immuno-
therapy are usually matured with cytokine cocktails [29] to
induce CCR7 expression so that they acquire the capacity to
migrate to the lymph nodes and are able to stimulate a T
cell response. This approach is likely to abrogate the imma-
ture phenotype of MoDC. In addition, it is not only a
matter of triggering immune responses, but also of direct-
ing them to the target tissues; although these DC may enter
lymph nodes directly and stimulate T cells, they are unlikely
to give tissue-homing potential to those stimulated cells, as
it is the source of DC and not the lymph node cells or
stroma that determines the homing property of the stimu-
lated T cells [11]. Thus, even if MoDC enter the lymph and
generate antigen-specific T cells, the lack of homing
markers of MoDC may cause the failure to induce a tissue-
specific homing profile on T cells.
An alternative approach would be to induce homing
markers directly on MoDC, so that they would migrate to
the target tissue and once there, following conditioning by
the tissue microenvironment [16], enter the respective
lymph nodes (mesenteric and/or Peyer’s patches in the gut)
to perform antigen presentation and imprint their own
homing profile on responding T cells. However, intestinal
tissue microenvironment not only induces CCR7 expres-
sion on DC [16], it also affects their phenotype and func-
tion; when blood DC are conditioned with inflamed colonic
microenvironment from UC patients, DC lose their homeo-
static properties and imprint a skin-homing profile on T
cells in the absence of RA [28]. Therefore, a major concern
regarding use of DC for immunotherapeutic purposes in
IBD is that RA-MoDC could potentially adopt a proinflam-
matory phenotype and function in vivo in the inflamed
colonic microenvironment, contributing to the ongoing
inflammation [26,27]. However, RA-MoDC maintained
their regulatory phenotype even in the presence or an
inflamed microenvironment derived from UC patients
(Fig. 6); a gut-specific immunomodulation might thus be
achieved with such cells, negating the necessity for systemic
immunosuppression produced with current treatments.
However, a recent study demonstrated that RA-conditioned
DC adopt proinflammatory properties in the presence of
IL-15, abrogating oral tolerance to dietary antigens [30].
Several differences between these studies may account for
the discrepancies. The major difference is the use of human
material for this study compared with murine models; data
from animal models may not be transferrable directly into
human mechanisms of disease [31]. Also, the MoDC in this
study were exposed to an inflamed colonic microenviron-
ment derived directly from human UC colonic biopsies
rather than IL-15; our previous studies suggest that IL-6 is
the dominant cytokine in UC pathogenesis [28]. Finally,
higher RA concentrations were used to pulse MoDC in this
study. These factors may explain why RA-pulsed DC were
not recruited towards a proinflammatory phenotype when
exposed to an intestinal microenvironment from UC
patients.
RA is a key player of immune homeostasis in the gut con-
trolling immunoglobulin (Ig)A switching of B cells, the
development of T cells with a regulatory phenotype/
function and induction of gut-homing properties of stimu-
lated B and T cells [14,21–23,32]. RA also mediates
acquisition of gut-homing properties on human DC and
regulates their ability to imprinting homing properties onto
stimulated T cells [16,33], while decreasing their T cell
stimulatory capacity [34], presumably through secondary
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transforming growth factor (TGF)-b induction [35]. We are
aware that we did not study the capacity of RA-MoDC to
induce regulatory T cells. That is because our recent evi-
dence has shown that forkhead box protein 3 (FoxP3)
expression may not be a valid marker to identify T cells with
a regulatory phenotype; because its expression is dynamic,
dependent upon T cell densities, it is subsequently lost in
time following removal of the stimulant, and FoxP3+ T cells
developed in vitro do not perform a suppressive activity
[36]. However, we have shown that RA-MoDC displayed a
decreased stimulatory capacity in a dose-dependent fashion
(Fig. 4), even in the presence of LPS (Fig. 5) or an inflamed
microenvironment from UC patients (Fig. 6), and T cells
that they stimulated decreased their IFN-g production and
increased their IL-10 content (Fig. 6). Together, these results
suggest that RA had the capacity to rehabilitate homeless
MoDC with an immature and gut-homing phenotype and
the capacity to generate gut-homing T cells that were not
proinflammatory.
In summary, in addition to factors usually considered for
utilizing DC in immunotherapy, the homing profile of DC
themselves and, more importantly, their capacity to imprint
homing profiles on the T cells they stimulate will influence
a DC immunomodulatory approach. Our data suggest that
RA conditioning may increase the efficacy of MoDC as
therapeutic agents, providing tissue specificity and sus-
tained homeostatic effects for DC-specific therapy targeted
at mucosal inflammatory diseases with tissue compartmen-
talization. Therapeutic approaches for IBD would, ideally,
involve gut-specific prevention of dysregulated inflamma-
tion without compromising immunogenicity towards
harmful or invading pathogens; our data provide a potential
method of doing so while minimizing systemic immuno-
suppression, which is a side effect of almost all current IBD
therapies. Our findings could also be extended to other gas-
trointestinal autoimmune disease such as Crohn’s disease
and/or coeliac disease. Future studies may identify ways of
inducing other tissue-specific homing markers in order to
develop tissue-homing specific MoDC to perform tissue-
specific immunotherapy.
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